Mike Fratantoro

Journavx is an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. RT’s Three Key Takeaways - The FDA has approved Journavx (suzetrigine) 50 mg, a first-in-class non-opioid analge... See more

This story was originally published on ProPublica, a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox. “Not Just Measles”: Whooping Cough Cases Are Soaring as Vaccine Rates ... See more

For cystic fibrosis, new antibiotics and new takes on old treatment methods are needed to eradicate existing drug-resistant micro-organisms and prevent the development of new ones. John D. Zoidis, MD Cystic fibrosis is a disease caused by an inherited gen... See more